Trial Profile
EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CONTROL ARM (LEVOCETIRIZINE 5 MG) [ESTUDIO DE LA EFICACIA Y SEGURIDAD DEL ANTIHISTAMINICO V0114CP 2,5 MG EN EL TRATAMIENTO DE LA RINITIS ALERGICA ESTACIONAL. ESTUDIO ALEATORIZADO, DOBLE CIEGO, DE TRES RAMAS Y GRUPOS PARALELOS, QUE INCLUYE UNA RAMA DE PLACEBO Y OTRA DE CONTROL ACTIVO (LEVOCETIRIZINA 5 MG)].
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Aug 2021
Price :
$35
*
At a glance
- Drugs Levomequitazine (Primary) ; Levocetirizine
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Pierre Fabre
- 31 Jul 2021 Status changed from recruiting to discontinued.
- 27 Aug 2011 New trial record